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Abstract
Studies in diverse organisms have revealed a surprising depth to the evolutionary conservation of genetic modules. For
example, a systematic analysis of such conserved modules has recently shown that genes in yeast that maintain cell walls
have been repurposed in vertebrates to regulate vein and artery growth. We reasoned that by analyzing this particular
module, we might identify small molecules targeting the yeast pathway that also act as angiogenesis inhibitors suitable for
chemotherapy. This insight led to the finding that thiabendazole, an orally available antifungal drug in clinical use for 40
years, also potently inhibits angiogenesis in animal models and in human cells. Moreover, in vivo time-lapse imaging
revealed that thiabendazole reversibly disassembles newly established blood vessels, marking it as vascular disrupting
agent (VDA) and thus as a potential complementary therapeutic for use in combination with current anti-angiogenic
therapies. Importantly, we also show that thiabendazole slows tumor growth and decreases vascular density in preclinical
fibrosarcoma xenografts. Thus, an exploration of the evolutionary repurposing of gene networks has led directly to the
identification of a potential new therapeutic application for an inexpensive drug that is already approved for clinical use in
humans.
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Introduction
Systems biology has shown great promise in providing a better
understanding of human disease and in identifying new disease
targets. These methods typically leave off once the target is
identified, and further research transitions to established para-
digms for drug discovery. However, the vast majority of molecular
pathways that function in human disease are not specific to
humans, but rather are conserved across vertebrates and even to
very distantly related organisms. The remarkable growth of
genetic data from tractable model organisms implies that most
genetic modules relevant to human biology are currently best
characterized in non-human species. Such evolutionary conserva-
tion, even when the homology of the systems to the human case is
distant or perhaps non-obvious, should enable new drug design
strategies.
Clearly, identification of deeply conserved gene networks in
distant organisms opens the possibility of pursuing drug discovery
in those organisms. While traditional methods of drug discovery
focus on gene-by-gene rather than network- or system-level
similarities, we suggest that phenologs—gene networks that while
orthologous may nonetheless produce different phenotypes due to
altered usage or organismal contexts [1]—can provide a basis not
just for screening against a single protein, but also for simultaneous
drug discovery efforts against multiple targets in parallel. Given
the key roles that model organisms already play in biomedical
research, identification of such deep homologies should also allow
us to better leverage the particular strengths of the wide variety of
animal models in order to rapidly test candidate drugs found from
such an approach.
We recently developed a method for systematically discovering
phenologs, and this approach identified a conserved module that is
relevant to lovastatin sensitivity in yeast and is also responsible for
regulating angiogenesis in vertebrates [1]. Angiogenesis, the
process of forming new blood vessels, plays an essential role in
development, reproduction, and tissue repair [2]. Because the
vascular network supplies oxygen and nutrients to cancer cells as
well as to normal cells, angiogenesis also governs the growth of
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many types of tumors, and is central to malignancy [2–5]. The
vasculature is thus considered to be a major therapeutic target for
drug development. Some cancers, such as the most common and
deadly brain neoplasm, glioblastoma multiformae [6], are heavily
vascularized, but have not responded to current angiogenesis
inhibitors [7,8]. Because new agents that target the vasculature
would increase our arsenal for battling cancers resistant to current
therapies [2–5], there is a clear clinical need for novel approaches
to their identification.
Here, we have exploited data mining of genetic interactions in
yeast, in vivo time-lapse imaging in a non-mammalian vertebrate,
loss-of-function analysis in cultured human cells, and preclinical
xenografts in mice to identify and characterize a novel anti-
angiogenic small molecule (Figure 1). Excitingly, this compound
is already FDA approved for use in treating certain infections in
humans, making it an excellent candidate for rapid translation to
the clinic. This research exemplifies a general strategy for
exploiting deeply conserved genetic modules for drug screening,
characterized by screens focused not on single genes but rather
on conserved genetic modules and by a strong reliance on
tractable model organisms in order to speed the discovery of
therapeutics.
Results and Discussion
Identification of a Novel Small-Molecule Angiogenesis
Inhibitor
The remarkable conservation of a genetic module that controls
lovastatin sensitivity in yeast and angiogenesis in vertebrates ([1];
Figures 2AB and S1; Table S1) led us to test the possibility that
small-molecule inhibitors modulating the yeast pathway might also
act as angiogenesis inhibitors. Indeed, preliminary evidence
suggests that lovastatin itself at least partly inhibits angiogenesis
[9,10] and may even reduce the incidence of melanoma [11,12].
We therefore devised a strategy to exploit the evolutionary
repurposing of this module in order to direct our search (Figure 1).
Specifically, we desired to identify compounds in a manner that
did not require their mechanism of action or even their
biochemical target to match that of lovastatin; we thus employed
a genetic strategy in yeast in order to select compounds that
genetically interacted with this module. By computationally
mining available large-scale chemical sensitivity datasets [13],
candidate compounds were prioritized based upon their measured
synthetic genetic interactions with yeast genes, using clustering
algorithms to identify those compounds with genetic interaction
profiles most similar to that of lovastatin (Figure 2C; Table S2;
Figure S2). Notably, four out of eight prioritized chemicals were
already known to modulate angiogenesis, indicating strong
enrichment for angiogenesis effectors (Table S2).
One compound—thiabendazole (TBZ; 4-(1H-1,3-benzodiazol-
2-yl)-1,3-thiazole)—stood out because it has already been
approved by the U.S. Food and Drug Administration (FDA) for
systemic oral use in humans (as an anti-fungal and anti-helminthic
treatment). TBZ was initially marketed by Merck as Mintezol, and
is now off-patent and issued as a generic under the trade names
Apl-Luster, Mertect, Mycozol, Tecto, Tresaderm, and Arbotect.
TBZ has been used by humans since its FDA approval in 1967, so
its safety has been well-established. In animals, TBZ has no
carcinogenic effects in either short- or long-term studies at doses
up to 15 times the usual human dose [14,15]. Moreover, TBZ does
not appear to affect fertility in mice or rats, and it is not a mutagen
in standard in vitro microbial mutagen tests, micronucleus tests, or
host-mediated assays in vivo [14,15]. Thus, TBZ was an
outstanding candidate for further study.
Thiabendazole Inhibits Angiogenesis
We first tested the effect of TBZ on the expression of vascular-
specific genes in developing Xenopus embryos, which provide a
rapid, tractable, and accurate model for in vivo studies of
angiogenesis [16–19]. Using in situ hybridization to either the
apelin-receptor (aplnr) or the vascular ETS factor (erg), we found
that TBZ treatment severely impaired angiogenesis (Figure 3A–D).
This result was confirmed in living embryos in which vasculature
was visualized by expression of GFP under control of a kdr
enhancer/promoter fragment (Figure 3E–F) [19]. Notably, TBZ
also inhibited angiogenesis in a dose-dependent manner in
cultured human endothelial cells (HUVECs), suggesting that the
activity of TBZ is conserved in vertebrates (Figure 4). We then
sought to position the site of TBZ action relative to that of VEGF,
as this growth factor is central to both normal and pathogenic
angiogenesis [3,4]. In frog embryos, ectopic VEGF potently
induces ectopic angiogenesis [16], and this effect was blocked by
TBZ, suggesting that the drug acts downstream of this key
regulatory node (Figure S3).
These data implicate TBZ as an effective inhibitor of
angiogenesis. Importantly, we observed angiogenesis inhibition
in both human cells in vitro and in Xenopus embryos in vivo at a
concentration of 100–250 mM. This dose corresponds to 20–
50 mg/kg (Figures 3 and 4), which is notable because the oral
LD50 of MINTEZOL is 1.3–3.6 g/kg, 3.1 g/kg, and 3.8 g/kg in
the mouse, rat, and rabbit, respectively, and the human approved
recommended maximum daily dose is 3 grams, corresponding to
50 mg/kg for 60 kg patients. Finally, we note that the overall
morphology and patterning of TBZ-treated Xenopus embryos was
grossly normal at the stages when the vasculature was severely
disrupted (Figure S4). Consistent with this, TBZ has good safety
data in humans and model animals at the doses for which we
observe a specific inhibition of angiogenesis [14,15].
We next asked if angiogenesis inhibition may be a general
property of benzimidazoles. Examination of commercially avail-
able TBZ derivatives showed that this is not the case, with
benzimidazole itself inactive at doses up to 1 mM and adminis-
Author Summary
Yeast cells and vertebrate blood vessels would not seem to
have much in common. However, we have discovered that
during the course of evolution, a group of proteins whose
function in yeast is to maintain cell walls has found an
alternative use in vertebrates regulating angiogenesis. This
remarkable repurposing of the proteins during evolution
led us to hypothesize that, despite the different functions
of the proteins in humans compared to yeast, drugs that
modulated the yeast pathway might also modulate
angiogenesis in humans and in animal models. One
compound seemed a particularly promising candidate for
this sort of approach: thiabendazole (TBZ), which has been
in clinical use as a systemic antifungal and deworming
treatment for 40 years. Gratifyingly, our study shows that
TBZ is indeed able to act as a vascular disrupting agent
and an angiogenesis inhibitor. Notably, TBZ also slowed
tumor growth and decreased vascular density in human
tumors grafted into mice. TBZ’s historical safety data and
low cost make it an outstanding candidate for translation
to clinical use as a complement to current anti-angiogenic
strategies for the treatment of cancer. Our work demon-
strates how model organisms from distant branches of the
evolutionary tree can be exploited to arrive at a promising
new drug.
Genetic Reuse Reveals a Vascular Disrupting Agent
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Figure 1. Overview of the evolutionary method used to discover a novel vascular disrupting agent. Strict reliance on the evolutionary
conservation of the relevant gene module allowed for an experimental design exploiting the unique experimental advantages of each model
organism, thus speeding the search for novel angiogenesis inhibitors. (Vector female silhouette under Creative Commons Attribution 2.0 from ‘Keep
Fit’ Vector Pack, Blog.SpoonGraphics.)
doi:10.1371/journal.pbio.1001379.g001
Figure 2. Identification of candidate angiogenesis inhibitors based upon genetic interactions with a yeast gene module. (A)
Summary of the gene module (modified from [1]). Tests of genes associated with the yeast phenotype (lovastatin sensitivity) correctly identified novel
angiogenesis genes, as in [1] and additionally shown in (B) for the gene rab11b. Morpholino (MO) knockdown of rab11B induces vascular defects in
developing Xenopus laevis (frog) embryos, measured by in situ hybridization versus marker gene erg. ISV, intersomitic vein; PCV, posterior cardinal
vein; VV, vitellin vein. (C) In an unbiased hierarchical clustering of compounds by their synthetic genetic interaction profiles with yeast genes
(analyzing data from [13]), the action of TBZ is among those interacting with this gene module and also most similar to lovastatin, the signature
compound affiliated with the angiogenesis gene module; hence, TBZ is a likely candidate angiogenesis inhibitor. Here, complete linkage clustering
employing uncentered correlation coefficients is shown; additional clustering methods are illustrated in Figure S2.
doi:10.1371/journal.pbio.1001379.g002
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tration of other benzimidazoles causing diverse developmental
defects but not angiogenesis inhibition (Figure S5). These findings
are thus significant for demonstrating a high level of precision for
this evolutionary approach to drug discovery.
Thiabendazole Is a Vascular Disrupting Agent
We next sought to better understand the cellular basis for
angiogenesis inhibition by TBZ. In the course of our studies, we
noted an interesting feature of the vasculature in TBZ-treated
embryos: disconnected and scattered arrays of cells in which
vascular gene expression persisted (Figures 3B,D and S3).
Hypothesizing that such morphological defects in the absence of
changes to vascular gene expression may stem from direct
impairment of vessel integrity, we tested the ability of TBZ to
disrupt pre-existing vasculature by treatments at later stages, when
blood vessels were already well formed and patent [20]. TBZ
treatment elicited overt breakdown of established vasculature at
these stages (Figure S6).
The ability of TBZ to disassemble extant blood vessels was
especially significant because such an activity has recently drawn
the attention of cancer biologists [4,21,22]. A new class of drugs
called Vascular Disrupting Agents (VDAs) break down existing
vascular structures, thereby disrupting blood flow, particularly
within solid tumors [4,21,22]. No VDAs have as yet been
approved for use in humans, although several such agents are
therapeutically promising and are in phase II and III trials [4].
As a direct test of the vascular disrupting activity of TBZ, we
performed time-lapse imaging of developing vasculature. Using
Kdr-GFP transgenic embryos [19] and time-lapse confocal
microscopy [23], we could effectively image developing vascula-
ture in vivo for periods of up to 20 h. During this time, the growth
of existing vessels and the sprouting of new vasculature could be
easily followed (Figure S7; Movie S1). Treatment with TBZ
completely prevented growth and sprouting of vessels, and
moreover elicited a striking disintegration of established vessels
after ,90 min of exposure (Figures 5 and S8; Movie S2). Upon
Figure 3. TBZ inhibits angiogenesis in vivo in Xenopus embryos. Formation of Xenopus embryo veins is disrupted, marked by expression of
vascular reporter genes (A, B) erg and (C, D) aplnr, contrasting treatment with 1% DMSO control only (A, C) with 1% DMSO, 250 mM TBZ, treated at
stage 31 and imaged at stages 35–36 (B, D). PCV, posterior cardinal vein; ISV, intersomitic vein; VV, vitellin veins. Similarly, TBZ disrupts vasculature
imaged within a living Xenopus embryo and visualized by vascular specific GFP in kdr:GFP frogs from [19], contrasting the vasculature of stage 46
animals treated from stage 41 with the 1% DMSO control (E) or 1% DMSO, 250 mM TBZ (F). Scale bar, 200 mm.
doi:10.1371/journal.pbio.1001379.g003
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longer exposures, endothelial cells scattered and many underwent
dramatic rounding (Figures 5A and S8; Movie S2).
These data demonstrate the efficacy of TBZ as a vascular
disrupting agent. Previously defined VDAs can act either by
targeting endothelial cells for selective cell death (e.g., ASA404
[24]) or by disrupting endothelial cell behaviors (e.g., combrestatin
A4 [25]), and so we sought to distinguish between these two
possible mechanisms for TBZ action. We noted that treatment
with TBZ doses sufficient to severely perturb the vasculature
elicited only modest increases in apoptosis in cultured HUVECs
(Figure S9). Moreover, vascular gene expression in dispersed,
rounded kdr-GFP+ endothelial cells in vivo reliably persisted for up
to 17 h after TBZ treatment (Figures 3F, 5, and S8).
These data argue against a role for apoptosis in vascular
disruption by TBZ. To test this idea more directly, we performed
washout experiments. Compellingly, washout of the drug after
overt TBZ-induced endothelial cell dispersal and rounding
resulted in significant re-spreading of endothelial cells and re-
formation of vessels in living Xenopus embryos assessed by time-
lapse imaging (Figure 6; Movie S3). In several cases, widely
separated kdr-GFP-positive endothelial cells reconnected into
nascent vessels after washout of TBZ (Figure 6).
Finally, we found that treatment with TBZ significantly slowed
endothelial cell migration in a scratch wound assay using cultured
HUVECs (Figure 7AB). This quantitative in vitro assay with
mammalian cells, combined with our in vivo data from Xenopus,
demonstrate that TBZ disrupts established vasculature not by
eliciting cell death but rather by perturbing endothelial cell behavior.
Thiabendazole Acts via Tubulin and Rho Kinase to
Control Endothelial Cell Behavior
The effect of TBZ on endothelial cells is striking and rapid. Our
in vivo imaging of the vasculature revealed that endothelial cells
retract from one another and round up within 2 h of TBZ
treatment (Figures 5 and 6). Moreover, we observed that this effect
is reversible by washout within a similarly rapid time frame
(Figure 6). The rapid time-frames observed here argue that TBZ
may act at the level of the cytoskeleton to influence endothelial cell
behavior.
We first considered that, while not an assumption of the
phenolog approach (see above), TBZ may nonetheless impact the
vasculature by the same mechanism as lovastatin. Lovastatin
disrupts angiogenesis at least in part by perturbing the geranyl-
geranylation of the RhoA GTPase, thereby abrogating its activity
[10]. RhoA is a critical regulator of actin-based behaviors in all
animal cells [26], and the loss of RhoA signaling in endothelial
cells treated with lovastatin is directly linked to cytoskeletal
changes and inhibition of angiogenesis [10]. Indeed, inhibition of
angiogenesis by lovastatin can be overcome by addition of geranyl-
geranyl pyrophosphate (GGPP; [9,10]). We therefore used the
HUVEC scratch-wound closure model to quantitatively assess the
effects of GGPP addition on TBZ action. However, we found that
addition of GGPP did not reverse the action of TBZ on HUVEC
cell motility in this assay (Figure S10). Similarly, while TBZ has
been observed to affect the activity of porcine heart mitochondria
[27], we detected no differences in mitochondrial mass (measured
by MitoTracker Green signal) or mitochondrial membrane
potential (measured as the ratio of MitoTracker Red signal to
Mitotracker Green signal) (unpublished data), thus ruling out this
potential activity as being relevant.
We next considered the possibility that TBZ acted on the
vasculature at the level of the microtubule (MT) cytoskeleton,
because TBZ has been found to disrupt microtubule assembly and
dynamics in a number of cell types (e.g., [28–31]), and because
several currently-studied VDAs act as MT-disrupting agents
[21,32]. Curiously, TBZ had only a very slight effect on the gross
Figure 4. TBZ significantly disrupts tube formation in cultured human umbilical vein endothelial cells (HUVECs), an in vitro
capillary model. Here, we show effects of 1% DMSO-treated control (A) versus 1% DMSO, 100 mM TBZ (B) and 1% DMSO, 250 mM TBZ (C). Scale bar,
100 mm. (D) Tube disruption is dose-dependent and comparable to that from silencing known pro-angiogenic gene HOXA9.
doi:10.1371/journal.pbio.1001379.g004
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Figure 5. TBZ disrupts newly established vasculature, as visualized in vivo using time-lapse fluorescence microscopy within kdr:GFP
frogs. Retraction and rounding of vascular endothelial cells (arrowheads) is apparent in TBZ-treated embryos (A, time lapse of frogs treated as in
Figure 3) as compared with continued vascular growth in control animals (Figure S7). Scale bar, 80 mm. (B) A series with intermediate time points is
shown for a sub-region of that shown in (A). (B9) Schematics of the images in (B) indicate positions of specific cells.
doi:10.1371/journal.pbio.1001379.g005
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organization of the MT cytoskeleton in HUVEC cells in culture
(Figure S11A), but a quantitative analysis using mass-spectrometry
revealed a significant reduction in the abundance of several
tubulin proteins following treatment of HUVECs with TBZ
(Figure S11B).
Many MT-targeting VDAs act via hyper-activation of Rho
signaling [25,33,34], likely reflecting the key role of MT-binding
RhoGEFs [35]. We reasoned, therefore, that TBZ may also act via
increased Rho signaling, as the drug elicited several phenotypes
known to be associated with dysregulated Rho signaling (e.g., cell
rounding, re-distribution of actin filaments, and defects in cell
motility; Figure 7). To test this model directly, we asked if
disruption of Rho signaling might counteract the effects of TBZ.
Indeed, pharmacological disruption of Rho kinase function using
the small molecule Y27632 elicited a significant and dose-
dependent rescue of the TBZ-induced HUVEC cell motility
defect (Figure 7A,B). Together, these data suggest that vascular
disruption by TBZ results from reduced tubulin levels and hyper-
active Rho signaling.
Thiabendazole Slows Tumor Growth in a Mouse
Xenograft Model
It is hoped that VDAs may open new therapeutic avenues by
complementing the action of currently used angiogenesis inhibitors
(e.g., [4]). Moreover, the data above suggest that the mechanism of
TBZ action distinguishes it from VDAs such as ASA404, which act
by inducing endothelial cell apoptosis [24], but which failed to
show efficacy in a recent Phase III clinical trial for treatment of
lung cancer [36]. To begin to ask if TBZ may be useful in the
arena of cancer therapy, we tested the ability of TBZ to slow the
growth of solid vascularized tumors in a mammal. We therefore
employed a mouse xenograft model typical of those proven
valuable in indicating the effectiveness of anti-angiogenesis therapy
[37,38]. We found that TBZ treatment significantly slowed
HT1080 human fibrosarcoma xenograft growth in athymic Cre
nu/nu mice [39], as assessed by a time course of tumor size and
also by final tumor mass (Figure 8).
Our in vivo data from Xenopus, as well as our human in vitro
data, suggest that TBZ likely slows tumor growth by acting at the
level of the vasculature (Figures 3 and 4). Consistent with this
model, TBZ treatment did not alter the rate of proliferation in
HT1080 cells when cultured in vitro but did significantly impair
tumor microvessel density in xenografts (Figures 9 and S12). In
addition, we noted that treatment with TBZ did not alter the levels
of VEGF expressed or secreted by HT1080 cells, consistent with it
acting downstream of VEGF in tumor xenografts (Figure S13), as
it does in developing Xenopus embryos in vivo (Figure S3). Notably,
we employed a TBZ dose of 50 mg/kg for these experiments,
which is concordant with the FDA-approved maximum recom-
mended daily dose of TBZ in humans, suggesting the possibility of
chemotherapeutic use in humans.
Conclusions
In sum, an analysis of evolutionary repurposing of a genetic
module shared from yeast to humans has led directly to the
discovery that an orally available drug, thiabendazole, already
Figure 6. After disassembly of the vasculature by TBZ, washout of the drug leads to partial recovery of the vascular network. Two
time series are shown in (A) and (B), imaged as in Figure 5. Following washout, cells dissociated by TBZ treatment recommence cell elongation and
connection. Individual cells are indicated by arrows/asterisks. Scale bar in (A), 50 mm; in (B), 40 mm.
doi:10.1371/journal.pbio.1001379.g006
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FDA approved for clinical use in humans, also acts as an
angiogenesis inhibitor and vascular disrupting agent. Moreover,
these data establish TBZ as the only VDA currently approved for
human use (albeit for a different purpose). Our data suggest that,
even for antifungal or antihelmintic use, the possibility of side
effects related to vascularization should be considered, for
example, in patients with cardiovascular disease or to the fetus if
administered to pregnant women, for whom TBZ has not been
broadly tested. Significantly, while research on VDAs has largely
centered on cancer therapy, their use may also provide new
therapeutic avenues for non-malignant diseases, such as diabetic
retinopathy and macular degeneration [40,41]. With more than
40 years of human use, the low cost and generic availability of
TBZ make it a compelling candidate for translation into the clinic
as a VDA.
Finally, this research emphasizes the advantages of an
evolutionary approach to drug discovery, in which the natural
experimental strengths of various organisms can be exploited to
accelerate our understanding of a conserved genetic module.
Importantly, this approach proceeded from a gene module-based
discovery strategy and proved effective even though the associated
organismal phenotypes were entirely unrelated. Curiously, at least
two other known antifungal drugs can also act as angiogenesis
inhibitors. Itraconazole, an azole antifungal drug otherwise
structurally unrelated to TBZ and acting via different mechanisms,
was identified as an angiogenesis inhibitor via high-throughput
screening [42]. This observation, in addition to the dual anti-
fungal and anti-angiogenic properties of lovastatin [9,10,43],
suggests additional interesting evolutionary connections between
the processes of yeast cell wall metabolism and vertebrate
angiogenesis. Such evolutionary connections further support the
yeast cell wall-relevant activity of TBZ, from among its multiple
pharmacological targets, as being the relevant activity for
angiogenesis. Thus there is no reason to suspect that a more
Figure 7. TBZ impedes migration of HUVECs in a wound scratch assay, but treatment with the Rho Kinase inhibitor Y27632 reverses
TBZ’s effects. (A) The effects of 1% DMSO-treated control versus 1% DMSO, 250 mM TBZ, and 1% DMSO, 250 mM TBZ, 10 mM Y27632. Scale bar,
200 mm. (B) quantifies the dose-dependent suppression of TBZ inhibition by Y27632. Error bars represent the mean 6 1 s.d. across 3 wells (1 of 3
trials). TBZ results in disorganization of actin stress fibers, as shown in (C) for 1% DMSO-treated control versus 1% DMSO, 250 mM TBZ-treated cells.
Scale bar, 20 mm.
doi:10.1371/journal.pbio.1001379.g007
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highly targeted agent could not be repurposed in a similar fashion.
Overall, these results suggest that a fundamental understanding of
systems biology will prove to be directly relevant to drug discovery,
complementing traditional screening approaches to pharmaco-




Compound genetic interaction profiles were downloaded from
http://chemogenomics.stanford.edu:16080/supplements/global/
download.html. We employed the p values reported for fitness
defects in the yeast homozygous deletion collection for all analyses
[13]. Candidate angiogenesis inhibitors were prioritized that
consistently clustered with lovastatin across different choices of
similarity measures and hierarchical clustering algorithms, specif-
ically centered and uncentered correlation, Spearman rank
correlation, absolute correlation (centered and uncentered),
Euclidean distance, and City-block distance, employing centroid
linkage, complete linkage, single linkage, or average linkage
clustering. Clustering results were visualized with Cluster 3.0
(http://bonsai.hgc.jp/,mdehoon/software/cluster/software.htm)
and Java TreeView (http://jtreeview.sourceforge.net/).
Figure 8. TBZ slows the growth of human HT1080 fibrosarcoma xenograft tumors in athymic Cre nu/nu mice. Tumors are significantly
reduced in size in TBZ-treated animals (A), shown in (B) biopsied from mice after 27 d of 50 mg/kg (corresponding to 250 mM) TBZ treatment, and
quantified in (C) and (D) (1 of 2 trials).
doi:10.1371/journal.pbio.1001379.g008
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Xenopus Embryo Manipulations
Female adult Xenopus were ovulated by injections of human
chorionic gonadotropin, and eggs were fertilized in vitro and
dejellied in 3% cysteine (pH 7.9) and subsequently reared in 1/36
Marc’s modified Ringer’s (MMR) solution. For microinjections,
embryos were placed in a solution of 2% Ficoll in 1/36MMR
solution, injected using forceps and an Oxford universal manip-
ulator, reared in 2% Ficoll in 1/36MMR to stage 9, then washed
and reared in 1/36 MMR solution alone. For bilateral rab11b
knock-down experiments, the posterior cardinal vein and inter-
somitic veins were targeted by injecting Morpholino antisense
oligonucleotides (MOs) into the two ventral cells equatorially at the
four-cell stage. For unilateral knockdown, only one ventral cell was
injected. MOs were injected at 40 ng per blastomere. For the
experiments to see the drug effects, embryos were placed in a
solution of each chemical dissolved in 1% DMSO diluted in 1/36
MMR during indicated stages. For bead micro-surgery implanta-
tion, Affi-Gel Blue Gel beads (Bio-Rad) were soaked with 0.7 mg/
ml recombinant mouse VEGF 164 aa (R&D systems) or BSA as a
control. Whole-mount in situ hybridization for erg and aplnr was
performed as described [44].
Morpholino Oligonucleotides and cDNA Clones
Erg and aplnr cDNAs were obtained from Open BioSystems (erg:
IMAGE:5512670, aplnr: IMAGE:8321886). Translation-blocking
antisense morpholinos for rab11b were designed based on the
sequences from the National Center for Biotechnology Informa-
tion database (accession number: BC082421.1). MOs were
obtained from Gene Tools with the following sequence: 59-
CGTATTCGTCATCTCTGGCTCCCAT-39.
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were
purchased from Clonetics, and were used between passages 4 and
9. HUVECs were cultured on 0.1% gelatin-coated (Sigma) plates in
endothelial growth medium-2 (EGM-2; Clonetics) in tissue culture
flasks at 37uC in a humidified atmosphere of 5% CO2.
In Vitro Angiogenesis Assays
HUVECs (104 cells) were seeded in a 96-well plate coated with
50 ml of ECMatrix (Chemicon) or Matrigel (BD Bioscience)
according to the manufacturer’s instructions. Cells were incubated
for 16 h on EGM-2 containing thiabendazole, dissolved in 1%
DMSO. Negative control cells were treated with 1% DMSO in
the same manner. As a positive control, siRNA versus the human
HoxA9 sequence [45] was transfected into HUVECs using
Lipofectamine RNAiMAX (Invitrogen) according to the manu-
facturer’s instructions. Tube formation was observed using an
inverted microscope (Nikon, eclipse TS100), and branch points
were measured using ImageJ software (http://rsb.info.nih.gov/ij).
Cell Migration Assays
HUVECs (1.26105 cells) were seeded into 24-well plates for
24 h, and the monolayers were wounded identically. Then, cells
were washed with PBS and treated with EBM-2 containing 1%
DMSO or 250 mM TBZ dissolved in 1% DMSO with a
combination of Y27632 or GGPP (Sigma). In the case of
Y27632 treatment, cells were preincubated for 2 h before
wounding. Cells were photographed at time zero and after 15 h,
and the ratios of cell free area [(0 h–15 h)/0 h] were calculated.
Xenograft Model
Specific pathogen-free athymic Cre nu/nu mice were purchased
from Charles River Laboratories. The HT1080 human fibrosar-
coma cell line was obtained from the American Type Culture
Collection (ATCC). HT1080 cells were cultured in DMEM
(Gibco) containing 10% fetal bovine serum (FBS, Gibco) in tissue
culture flasks at 37uC in a humidified atmosphere of 5% CO2. In
order to generate a mouse xenograft model, a suspension of the
HT1080 cells (36106 in 50 ml PBS) mixed with an equal volume of
Matrigel (BD Bioscience) was subcutaneously implanted into the
flank region of 7–8-wk-old female mice. Upon establishment of
tumors (approx. 40 mm3), mice were given daily intraperitoneal
injections of 1 mg thiabendazole (Sigma-Aldrich), suspended in
20 ml DMSO. Mice weighed on average 20 grams; this dose thus
corresponded to 250 mM TBZ. As a control, an equal volume of
DMSO was injected in the same manner. Tumor growth was
monitored by measuring the length and width of each tumor using
digital calipers, and the tumor volume in mm3 calculated by the
formula: Volume= (width)26length/2. Upon a tumor reaching
the maximum size permitted by the Institutional Animal Care and
Use Committee (1.5 cm in diameter), the mouse was sacrificed,
and the tumor excised.
Immunohistochemistry
Each tumor was fixed with 4% paraformaldehyde in PBS, and
cryostat sections were processed. After blocking with 5% goat
serum in PBST (0.3% Triton X-100 in PBS) for 1 h at room
Figure 9. Blood vessel density is significantly reduced within TBZ-treated tumors. (A) and (B) show tumor vasculature visualized by
immunohistochemistry of microdissected tumor sections using an anti-CD31 (PECAM-1) antibody staining for vasculature in the region of highest
vessel density (‘‘hot spots’’; scale bar, 100 mm), and the total area of PECAM-1 staining above a fluorescence intensity threshold (arbitrary units) is
quantified in (C).
doi:10.1371/journal.pbio.1001379.g009
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temperature, sectioned tissues were incubated with anti-mouse
CD31 antibody, hamster clone 2H8, 1:100 (Millipore). After
several PBST washes, samples were incubated for 2 h at room
temperature with FITC-conjugated anti-hamster IgG antibody,
1:1,000 (Jackson ImmunoResearch).
In order to determine the effect of thiabendazole on prolifer-
ation and apoptosis, 26105 HUVECs or HT1080 were cultured in
6-well plates and treated with thiabendazole dissolved in 1%
DMSO. Control cells received 1% DMSO. For actin and tubulin
cytoskeleton analysis, 76104 HUVECs were seeded. After 24 h,
cells were fixed using 4% paraformaldehyde in PBS. Cell
membranes were permeabilized with 0.2% Triton X-100 in
PBS, and nonspecific immunobinding sites were blocked with 5%
goat serum for 1 h at room temperature. Cells were incubated
with primary antibodies to Caspase-3 (Abcam), Phospho-histone
H3 (Ser10; Millipore), or b-tubulin (Sigma) at 4uC overnight. After
washing with PBST, primary antibodies were detected by Alexa
Fluor-488 or 555 goat anti-rabbit immunoglobulin (IgG). Alexa
Fluor 488 phalloidin (Invitrogen) and/or 49,6-Diamidino-2-
phenylindole (Sigma) were added as needed.
Immunostaining for Xenopus was performed as previously
described [46]. Embryos at stage 35–36 were fixed in 16
MEMFA. 12/101 (1:500; DSHB) and primary antibodies were
detected with Alexa Fluor-488 or 555 goat anti-mouse Immuno-
globulin (IgG).
Imaging and Image Analysis
Immunohistochemistry experiments and kdr:GFP transgenic
Xenopus laevis were imaged on an inverted Zeiss LSM5 Pascal
confocal microscope and Zeiss 5-LIVE Fast Scanning confocal
microscope. Confocal images were processed and cropped in
Imaris software (BITPLANE) and Adobe Illustrator and Adobe
Photoshop for compilation of figures.
Mass Spectrometry
HUVECs were treated with 1% DMSO or 1% DMSO,
250 mM TBZ for 24 h, and lysed by Dounce homogenization in
low salt buffer (10 mM Tris-HCl, pH 8.8, 10 mM KCl, 1.5 mM
MgCl2) with 0.5 mM DTT and protease inhibitor mixture
(Calbiochem). 2,2,2-trifluoroethanol was added to 50% (v/v) for
each sample, and samples were reduced with 15 mM DTT at
55uC for 45 min and then alkylated with 55 mM iodoacetamide at
room temperature for 30 min. Following alkylation, samples were
diluted in digestion buffer (50 mM Tris-HCl, pH 8.0, 2 mM
CaCl2) to a final 2,2,2-trifluoroethanol concentration of 5% (v/v)
and digested using proteomics grade trypsin (Sigma) at 1:50
(enzyme/protein) concentration and incubated at 37uC for 4–5 h.
Digestion was halted with the addition of 1% formic acid (v/v),
and sample volume was reduced to 200 ml by SpeedVac
centrifugation prior to loading on HyperSep C-18 SpinTips
(Thermo). Samples were eluted (60% acetonitrile, 0.1% formic
acid), reduced to 10 ml by SpeedVac centrifugation, and
resuspended in sample buffer (5% acetonitrile, 0.1% formic acid).
Tryptic peptides were then filtered through Microcon 10-kDa
centrifugal filters (Millipore), and collected as flow-through.
Peptides were chromatographically separated on a Zorbax
reverse-phase C-18 column (Agilent) via a 230 min 5%–38%
acetonitrile gradient, then analyzed by on-line nanoelectrospray-
ionization tandem mass spectrometry on an LTQ-Orbitrap
(Thermo Scientific). Data-dependent ion selection was performed,
collecting parent ion (MS1) scans at high resolution (60,000) and
selecting ions with charge .+1 for collision-induced dissociation
fragmentation spectrum acquisition (MS2) in the LTQ, with a
maximum of 12 MS2 scans per MS1. Ions selected more than
twice in a 30 s window were dynamically excluded for 45 s. MS2
spectra were interpreted using SEQUEST (Proteome Discoverer
1.3, Thermo Scientific), searching against human protein-coding
sequences from Ensembl release 64 [47]. Search results were then
processed by Percolator [48] at a 1% false discovery rate. Protein
groups were generated comprising proteins with identical peptide
evidence, omitting those proteins whose observed peptides could
be entirely accounted for by other proteins with additional unique
observations. Differential expression of proteins across TBZ-
treated and control samples was quantified from the MS2 spectral
count data using the APEX method of relative quantification [49].
Western Blotting and ELISA
HT1080 (26105 or 46104cells) were cultured in 6-well plates
and treated with 1% DMSO or 1% DMSO, 250 mM TBZ for
24 h. Cells were lysed in cell lysis buffer (Cell Signaling
Technology) containing 1 mM PMSF, and analyzed by SDS-
PAGE and Western blotting using anti-VEGF (Santa Cruz, A-20)
or anti-GAPDH (Cell Signaling Technology) antibodies. The
secreted VEGF level in culture medium was determined by
enzyme-linked immunosorbent assay (ELISA; R&D) according to
the manufacturer’s instructions.
Supporting Information
Figure S1 Unilateral morpholino (MO) knockdown of rab11b
induces vascular defects in developing Xenopus laevis (frog) embryos,
showing the control versus knockdown sides of the same animal
and measured by in situ hybridization versus marker gene aplnr.
ISV, intersomitic vein; PCV, posterior cardinal vein.
(TIF)
Figure S2 In yeast chemical genetic interaction datasets [13],
TBZ treatment consistently clustered with lovastatin treatment
across different choices of similarity measures and clustering
algorithms. Three cases out of 19 trials are illustrated here,
organized as in Figure 2C.
(TIF)
Figure S3 TBZ inhibits ectopic angiogenesis (note the doubled
PCV in the left panel) stimulated by Affy-gel blue beads (75–
150 mm diameter, indicated by white arrowheads) pre-soaked with
0.7 mg/ml vascular endothelial growth factor (VEGF) and
microsurgically implanted into developing Xenopus embryos,
assaying for the vasculature by ISH versus erg or aplnr (showing
data for erg). 6 of 8 control animals developed ectopic PCV or VV,
as opposed to 0 of 9 TBZ-dosed animals (p value = 0.0023). TBZ-
treated embryos show notably disorganized (cellularized) vascula-
tures.
(TIF)
Figure S4 Somitic muscle, defined with the 12/101 antibody, on
1% DMSO, 250 mM, TBZ-treated Xenopus embryo, is normal
compared to 1% DMSO control. Both were treated at stage 31
and imaged at stages 35–36.
(TIF)
Figure S5 Tests of commercially available TBZ variants indicate
that in vivo angiogenesis inhibition activity in Xenopus varies
strongly across benzimidazoles and suggests necessary chemical
moieties (for example, suggesting that the thiazole group, or at
least its nitrogen, is important to activity).
(TIF)
Figure S6 TBZ treatment shortly after the posterior cardinal
vein (PCV) is established (stage 36) causes Xenopus vascular
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structures to re-cellularize in vivo, shown by in situ hybridization
versus aplnr at stage 39.
(TIF)
Figure S7 Blood vessel development visualized in vivo using
time-lapse fluorescence microscopy of the vasculature developing
within a living Xenopus embryo. Arteries and veins are visualized as
in Figures 3 and 5 by vascular-specific kdr:GFP frogs from [19],
showing the vasculature of stage 46 animals treated from stage 41
with the 1% DMSO control. Scale bar, 80 mm.
(TIF)
Figure S8 Retraction and rounding of vascular endothelial cells
(blue arrowheads) is apparent at higher magnification in TBZ-
treated embryos (as in Figures 3 and 5). Scale bar, 30 mm.
(TIF)
Figure S9 TBZ treatment (A) increases apoptosis and (B)
decreases proliferation of HUVEC cells cultured on 0.1% gelatin,
but only by approximately 2-fold. Both changes are significant
under a t test (p=0.015, p=0.01, respectively). Error bars
represent mean 6 1 s.d. across 14–16 fields of view of 2006
magnification confocal microscopy cell images across 2–3
independent experiments. Scale bar, 100 mm.
(TIF)
Figure S10 (A, B) GGPP does not reverse the impeded
migration of HUVECs in a wound-scratch assay. (A) shows effects
of 1% DMSO-treated control versus 1% DMSO, 250 mM TBZ,
and 1% DMSO, 250 mM TBZ, 25 mM GGPP. (B) shows
quantification as a function of varying GGPP concentrations.
Error bars represent mean 6 1 s.d. across 3 wells (1 of 2 trials).
Scale bar, 200 mm.
(TIF)
Figure S11 Immunohistochemical analysis of b-tubulin does not
show a definite distinction between 1% DMSO-treated control
and 1% DMSO, 250 mM TBZ-treated HUVECs (A), but tubulins
in HUVECs identified by a quantitative mass-spectroscopy
analysis were significantly reduced with TBZ treatment (B). Scale
bar in (A), 20 mm.
(TIF)
Figure S12 TBZ treatment does not significantly affect the
proliferation of HT1080 cells. Error bars represent mean 6 1 s.d.
across 14–15 fields of view of 2006 magnification confocal
microscopy cell images across 2 independent experiments. Scale
bar, 100 mm.
(TIF)
Figure S13 TBZ does not significantly alter intracellular or
secreted VEGF levels in HT1080 cells. VEGF levels in HT1080
cells and conditioned medium were measured in 1% DMSO-
treated control and 1% DMSO, 250 mM TBZ-treated HT1080
cells, assaying cellular VEGF by Western blotting (A) and secreted
VEGF by ELISA (B). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) level was measured for a Western blotting control.
(TIF)
Movie S1 In vivo vascular development in kdr:GFP frogs.
(M4V)
Movie S2 Disassembly of vasculature in kdr:GFP frogs following
addition of 250 mM TBZ.
(M4V)
Movie S3 Disassembly of vasculature and reassembly after
addition and then washout of 250 mM TBZ in kdr:GFP frogs.
(M4V)
Table S1 Conserved genes in the vertebrate angiogenesis
defect/yeast lovastatin sensitivity gene module. Bold text indicates
vertebrate genes whose angiogenesis roles were known or
confirmed by the literature; italic text indicates genes whose roles
were predicted in [1] and confirmed in frogs and HUVEC cells in
[1] and Figures 2B and S1.
(DOC)
Table S2 Compounds computationally prioritized as candidate
angiogenesis effectors. Nineteen alternate hierarchical clustering
trials were performed varying the choice of clustering algorithm
and the measure of similarity between drug-gene interaction
profiles (from [13]), as described in Materials and Methods, and
compounds were selected by the frequency with which they
occurred in the same subcluster as lovastatin.
(DOC)
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